Cyclin-dependent kinase inhibitors (cdkis), such as p21, are believed to control proliferation through an ability to function as stoichiometric antagonists of cyclin-dependent kinases (cdks). The p21 gene is a direct transcriptional target for the p53 protein, and its activation is likely to be important in eecting the p53 response. It is widely accepted that p21 can in¯uence cell cycle progression by controlling the activity of cdks that act on the retinoblastoma tumour suppressor protein (pRb) which, in a hypophosphorylated state, associates with E2F transcription factors to prevent the activation of genes required for progression into S phase. Phosphorylation of pRb by G1 cdk complexes releases E2F and thereby enables progress through the cell cycle. Here, we describe results which suggest a p21-dependent mechanism that facilitates the regulation of E2F through a pathway that is independent of the cdk control of pRb activity. As p21 can associate with E2F subunits, it is possible that these eects are exerted through a complex with E2F. Furthermore, we ®nd that p21 can regulate transcription in vitro. The results suggest that p21 may control E2F activity through a pathway that acts independently of pRb.
Introduction
The p21 protein, which is encoded by Waf1/Cip1, plays a signi®cant role in mediating the physiological eects of the p53 response (Dulic et al., 1994; Brugarolas et al., 1995; Deng et al., 1995; Ko and Prives, 1996) . Upon the activation of p53 during cellular stress, the ability of p53 to function as a sequence-speci®c transcription factor is believed to result in the activation of a panel of p53 responsive genes, the concerted action of which lead to an inhibition of cell cycle progression or the induction of apoptosis (Levine, 1997) . The p21 gene is a direct transcriptional target for p53 and has an important role to play in mediating the p53 response to cellular stress (El-Deiry et al., 1993 .
Cyclin-dependent kinases (cdks) are protein complexes, composed of a regulatory cyclin and catalytic cdk subunit, which orchestrate cell cycle transitions (Sherr and Roberts, 1995) . Cdk-inhibitors of the p21-like group function as stoichiometric antagonists of cdk activity by binding to both subunits of the complex (Xiong et al., 1993; Russo et al., 1996) . The inhibition of cdk activity by p21 is likely to be important in the control of cell cycle progression, and it is widely believed that a principal pathway through which p21 regulates growth is mediated through an indirect mechanism via the control of E2F activity (Sherr and Roberts, 1995) . In this respect, it is known that G1 cdks are in¯uential in mediating the phosphorylation control of the retinoblastoma tumour suppressor protein (pRb) which, in the hypophosphorylated state, interacts with and negatively regulates the activity of E2F transcription factors, thus preventing the activation of E2F-responsive target genes which, for the most part, promote proliferation (Weinberg, 1995) .
However, p21 is endowed with at least one other activity that can in¯uence growth, exerted through the C-terminal region, which enables p21 to bind to the proliferating cell nuclear antigen (PCNA; Chen et al., 1994; Waga et al., 1994; Gulbis et al., 1996) . PCNA functions as an accessory factor for DNA polymerase activity in replication and repair and, by interacting with PCNA, p21 prevents PCNA-dependent replication whilst failing to inhibit PCNAdependent excision repair (Li et al., 1994; Shivji et al., 1994) . Taken together, studies on the properties of p21 in the regulation of cdk and PCNA activity identify p21 as a multifunctional protein, and suggest that p21 has acquired the capacity to act through pleiotrophic mechanisms in order to eect cell cycle arrest.
It is interesting to note that certain viral oncoproteins, such as the E7 protein of human papilomavirus (HPV)16, form a physical complex with p21 (Funk et al., 1997; Jones et al., 1997) . The HPV16 E7 protein can also associate with and inactivate the growth regulating properties of pRb, which thereafter leads to an increase in E2F activity in a process that is likely to enhance cell cycle progression (Vousden, 1995) . As p21-mediated growth control appears to be exerted upstream of pRb through the regulation of cdk activity and maintenance of pRb in a hypophosphorylated growth-suppressing state, the physiological rationale of the interaction between E7 and p21 remains to be determined.
Interestingly, however, although the p21 gene can be transcriptionally induced by p53, it is known that its expression is not solely under the control of p53 and further that it can be uncoupled from cell cycle progression (Halevy et al., 1995; Missero et al., 1995 Missero et al., , 1996 Ponten et al., 1995; Parker et al., 1995; Di Cunto et al., 1998) . For example, p21 is induced during the dierentiation process in distinct cell lineages. In the intestine, p21 levels are increased in post-mitotic cells but down-regulated during the later stages of differentiation (Ponten et al., 1995) . In the keratinocytes of hair follicles, p21 is expressed in a small group of post-mitotic cells adjacent to a population of proliferating keratinocytes in the lower bulb, yet in the upper region of dierentiated cells little p21 expression is evident (Di Cunto et al., 1998) . Indeed, the forced expression of p21 in terminally dierentiated cells causes the transcription of genes that encode terminal markers of dierentiation to cease through a mechanism that is independent of cell cycle control (Di Cunto et al., 1998) , suggesting that p21 may be endowed with additional regulatory properties, unrelated to the direct control of the cell cycle, that have yet to be elucidated.
Here, we report data that are consistent with a new pathway of control for p21. Speci®cally, we have found that p21 can inactivate E2F transcriptional activity in a fashion that cannot easily be attributed to the control of upstream cdks that regulate the pRb/E2F interaction. Furthermore, since we ®nd that p21 possesses an intrinsic capacity to regulate transcription and can form a complex with E2F subunits, it is possible that this mechanism of control is facilitated through an interaction between p21 and E2F. The results imply a new level of regulation by p21 through a pathway that is independent of pRb. Figure 1 Inactivation of E2F-dependent transcription by p21. (a) The human cyclin A promoter (7214 to +100; 2.0 mg) fused to luciferase was introduced into U2OS cells together with expression vectors encoding E2F-1 (track 3; 2.5 mg), E2F-1 Y411C (track 6; 2.5 mg) or E2F-1D5 (track 9; 2.5 mg) and p21 (tracks 2, 3, 5, 6, 8 and 9; 2.0 mg). Throughout pSV-bgal (2.0 mg) was included in each transfection as an internal control, and the relative activity of luciferase to b-galactosidase determined. The total amount of DNA was made equivalent with empty vector. The data presented show a typical result, and re¯ect average values from two sets of data. (b) The human cyclin A promoter fused to luciferase (2.0 mg) was introduced into U2OS cells together with expression vectors encoding p21 (tracks 3, 6 and 9; 2 mg), E2F-1 (tracks 2 and 3; 4 mg), E2F-1D5 (tracks 8 and 9; 4 mg), E2F-1 Y411C (tracks 5 and 6; 4 mg). Throughout pSV-bgal was included as an internal control and the values calculated as described in (a). (c) The human cyclin A promoter fused to luciferase (2.0 mg) was introduced into U2OS cells together with expression vectors for p21 (track 3; 2 mg), pRb (track 4; 2.5 mg) and E2F-1 Y411C (tracks 2, 3 and 4; 4 mg). The internal control and values were calculated as described for (a)
Results

Control of E2F activity by p21
The eect of p21 on E2F-dependent transcription was assessed by transfecting into U2OS cells an expression vector encoding p21 with or without E2F-1, together with the E2F-responsive human cyclin A promoter (Schulze et al., 1995; Zwicker et al., 1995) . The presence of p21 abrogated transcription from the cyclin A promoter, an eect that was alleviated by co-expression of E2F-1 (Figure 1a , compare tracks 1, 2 and 3) and speci®c for the E2F binding site (data not shown). Since p21 can in¯uence the level of hypophosphorylated pRb through the inactivation of G1 cdks (Sherr and Roberts, 1995) , and because E2F-1 can physically interact with pRb (Flemington et al., 1993; Helin et al., 1993) , such an eect could have arisen if the level of E2F-1 was sucient to titrate and thus inactivate the repressing form of pRb. To rule out this possibility, two dierent mutant E2F-1 proteins, Y411C and D5, which are severely compromised in their pRb binding capacity (Helin et al., 1993; Krek et al., 1994) , were co-expressed with p21. Both of the E2F-1 mutants could override the inactivation imposed by p21 on E2F-dependent transcription as eciently as wild-type E2F-1 (Figure 1a , compare tracks 4, 5 and 6, and 7, 8 and 9), suggesting that the interaction between pRb and E2F-1 was not the only mechanism responsible for the observed eect of p21 on E2F activity.
Although the E2F-1 mutants could override the eect on transcription caused by the expression of p21 they were, nevertheless, susceptible to inactivation by p21 because, in conditions where an increased level of wild-type E2F-1, Y411C or D5 induced cyclin A activity ( Figure 1b , tracks 2, 5 and 8) the coexpression of p21 lowered transcription to a constitutive level (Figure 1b , compare tracks 2, 5 and 8 with 3, 6 and 9). In the same experimental conditions we con®rmed that the activity of wild-type E2F-1 was susceptible to pRb inactivation and further that Y411C could not be inactivated by pRb (Figure 1c , compare tracks 1, 2, 3 and 4, and data not shown), again suggesting that a p21-dependent control of pRb phosphorylation was not the only cause of the observed eects on E2F activity.
Similar results on the regulation of E2F activity by p21 in a pRb-independent fashion have been reported previously (Dimri et al., 1996) . In that study the regulation of E2F was suggested to involve the in¯uence of p21 on the cyclin/cdk complex located in the spacer region of the p107 pocket region. However, since E2F-1 is regulated by pRb rather than p107 (Dyson, 1998) , such a possibility was an unlikely explanation for the observed eects of p21 on E2F-1 activity documented here. We therefore progressed on to consider other mechanisms that may be responsible for the down-regulation of E2F-1 by p21.
p21 can down-regulate transcription
A possible mechanism that could account for the inactivation of transcription from the cyclin A promoter was direct transcriptional regulation by p21 in a pRb-independent fashion. In order to test this idea we fused p21 to the Gal4 DNA binding domain and assessed the eect on the reporter construct pSV-GAL-tk which contains a Gal4 binding site located between the SV40 enhancer and Figure 2 Activity of Gal4-p21 hybrid proteins. (a) Summary of the transcriptional activity of pSV-GAL-tk in the presence of expression vectors encoding the indicated proteins. ++indicates wild-type activity of pSV-GAL-tk, and 7down-regulated transcription. (b) pSV-GAL-tk (2 mg) was introduced into U2OS cells together with expression vectors (4 mg) encoding Gal4 (track 2), pRb (track 3), Gal4-pRb (track 4), Gal4-RbD22 (track 5), Gal4-p107 (track 6), p21 (track 7) and Gal4-p21 (track 8). The total amount of DNA was made equivalent with empty vector. Throughout pSV-bgal (2 mg) was included as an internal control, and the data show a typical result and re¯ect average values from three independent sets of data
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Waf1/Cip1 L Delavaine and NB La Thangue Figure 3 Mutational analysis of p21. (a) pSV-GAL-tk (200 ng) was introduced into U2OS cells together with 2 mg of the indicated p21 expression vectors. Throughout pSV-bgal (2 mg) was included as an internal control, and the data shown re¯ect average values from three independent sets of results. The total amount of DNA was made up with empty vector. The diagram shows the cyclin, cdk and PCNA binding domains in p21 (Sherr and Roberts, 1995) . (b) The indicated p21 derivatives were introduced into U2OS cells and protein levels assessed by immunoblotting with anti-Gal4 as described. (c) Either pTG13 (tracks 1 ± 4; 2 mg), the human cyclin A promoter (tracks 5 ± 8; 2 mg), the human thymidine kinase (TK) promoter (tracks 9 ± 12; 2 mg) or pSV-GAL-tk (tracks 13 ± 17; 200 ng) was introduced into U2OS cells alone (tracks 1, 5, 9 and 13) or together with expression vectors encoding Gal4-p21 (tracks 2, 6, 10 and 15; 4 mg), Gal4-p21 28 ± 90 (tracks 3, 7, 11 and 16; 4 mg), Gal4-p21 1 ± 90 (tracks 4, 8, 12 and 17; 4 mg) or wild-type p21 (track 14; 4 mg). Throughout pSV-bgal (2 mg) was included as an internal control, and the data shown re¯ect average values from three independent sets of results. Details of pTG13, the cyclin A and thymidine kinase reporters, and pSV-GAL-tk are shown in the diagram the herpes simplex virus minimal thymidine kinase promoter ( Figure 2a ). We used the activity of Gal4-pRb and Gal4-p107 hybrids as controls, as previous reports (Bremner et al., 1995; Weintraub et al., 1995) have described their ability to repress transcription in contrast to Gal4-pRbD22, which carries a sequence derived from a naturally occurring mutant in the Rb gene; both Gal4-pRb and Gal4-p107 repressed transcription ( Figure 2a and b, compare tracks 1 through 6).
Strikingly, in these conditions we found that Gal4-p21 reduced the level of transcription to a similar extent as Gal4-pRb and Gal4-p107 (Figure 2a and b, compare tracks 4, 6 and 8), suggesting that p21, like pRb and p107, has the intrinsic capacity to regulate transcription. However, in order to in¯uence pSV-GAL-tk activity the results show that p21 had to be targeted to the promoter context and thus become located in a DNA binding context because, without the Gal4 DNA binding domain, there was an insigni®cant eect of p21 on transcription from pSV-GAL-tk ( Figure 2a and b, compare tracks 7 and 8). In turn, these data argue that the eect of p21 is not a general eect on transcription as the expression of p21 (without the Gal4 DNA binding domain) had little eect on pSV-GAL-tk activity ( Figure 2a and b, compare tracks 7 and 8).
The regions in p21 that are necessary for the regulation of transcription apparent in the Gal4-hybrid assay were investigated by fusing dierent parts of p21 to the Gal4 DNA binding domain ( Figure 3a ) and thereafter assessing the eect on the activity of pSV-GAL-tk. We found that the N-terminal half of p21 could down-regulate transcription, since Gal4-p21 1 ± 90 reduced the activity of pSV-GAL-tk as eciently as wild-type p21 ( Figure 3a) . A mutational analysis in the context of Gal4-p21 1 ± 90 highlighted the importance of the N-terminal region as the activity of Gal4-p21 28 ± 90 was severely compromised (Figure 3a) . Importantly, the Gal4-p21 derivatives used in the analysis were all expressed at similar levels ( Figure  3b ). Thus, when targeted to a promoter context p21 can inactivate transcription in a fashion that is dependent upon the integrity of the N-terminal half of the protein.
The promoters from the cell cycle-regulated genes cyclin A and thymidine kinase contain E2F binding sites (Slansky et al., 1993; Zwicker et al., 1995; Farnham et al., 1996) and, consistent with this feature, both promoters were aected by p21 and its mutant derivatives in a similar fashion (Figure 3c ). For example, Gal4-p21 and Gal4-p21 1 ± 90 lowered the level of transcription whereas Gal4-p21 28 ± 90 was inactive ( Figure 3c , tracks 5 through 12), a similar trend being apparent when the activity of these Gal4-p21 derivatives was assessed on Gal4-responsive pSV-GAL-tk reporter ( Figure 3c , compare tracks 5 to 17). Importantly, the transcriptional activity of a variety of promoters which lack E2F binding sites was not aected by p21, an example of which is shown here for pTG13 (Lee et al., 1998) , a promoter that is regulated by p53 (Figure 3b , compare tracks 1 to 4 and data not shown). These results suggest therefore that E2F can be regulated by p21, and imply that the mechanism of regulation may require p21 to be part of a DNA binding complex.
The regulation of E2F activity by p21 may occur through a cdk/pRb independent pathway Although the results are consistent with a mechanism of E2F control by p21 that is independent of a p21-dependent eect on the cdk/pRb pathway, it was necessary to assess this possibility in greater detail. To explore this issue we studied the properties of a number of mutant derivatives placed in the context of the Nterminal region of p21 (residue 1 to 90; Figure 4a ), a region which can regulate E2F activity and downregulate transcription as a Gal4 hybrid protein (Figures  2 and 3) . Two of the p21 mutants, namely p21 21, 24 and p21 D53 ± 58 , possess altered protein sequence in the cyclinbox and cdk subunit binding domain respectively and are known to be unable to inhibit cdk activity (Nakanishi et al., 1995; Lin et al., 1996) . Another p21 mutant, p21
, carries a mutation in the C-terminal region of the Nterminal domain that, based on the structural analysis of the closely related cdki p27 bound to a cyclin/cdk complex, would aect a region of p21 that ®ts into the catalytic domain of the cdk partner (Jerey et al., 1995) .
In the ®rst instance, we con®rmed the previously described properties of p21 21, 24 and p21 D53 ± 58 and, in Figure 4 (a) Summary of the p21 mutant derivatives; the numbers show the position of the altered or deleted residues.
(b) Eect of p21 mutant derivatives on cyclin/cdk kinase activity: expression vectors for the indicated Gal4-p21 proteins (placed in the context of p21 1 ± 90 2.5 mg) were introduced into U2OS cells as indicated. Immunocomplexes were collected with anti-cdk2 antisera as described and thereafter assayed for kinase activity using histone H1 as the substrate. Note that p21 21, 24 and p21 D53 ± 58 fail to inhibit cdk activity, in contrast to p21
, which possesses wild-type activity. Phosphorylated H1 is indicated. (c) The indicated Gal4-p21 proteins (placed in the context of p21 1 ± 90 ; 2.5 mg) were introduced into U2OS cells. Extracts were prepared and thereafter immunoblotted with antiGal4 as described
Waf1/Cip1 L Delavaine and NB La Thangue addition, investigated the ability of the new mutant p21 D76 ± 79 to regulate cdk activity. To perform this analysis, p21 1 ± 90 or one of the mutant derivatives (as a Gal4 hybrid) was introduced into U2OS cells and, after immunoprecipitation with an anti-cdk2 antiserum from extracts prepared from transfected cells, cdk activity was assessed using histone H1 as the substrate. High levels of cdk2 kinase activity were apparent in the cdk2 immunoprecipitate from the control treatment ( Figure  4b , track 2) whereas kinase activity was almost completely absent in p21 1 ± 90 transfected cells ( Figure  4b, track 3) , a result consistent with earlier reports on the role of the N-terminal region in regulating cdk activity (Chen et al., 1994; Li et al., 1994) . In contrast, we failed to detect any decline in cdk2 kinase activity in cells expressing p21 21, 24 or p21
, although wildtype levels of inhibition were apparent in cells transfected with p21 D76 ± 79 (Figure 4b , compare tracks 4, 5 and 6) and each p21 derivative was expressed at an equivalent level (Figure 4c ). From these results, we conclude that p21 21, 24 and p21 D53 ± 58 are poor antagonists of cdk2 kinase activity whereas p21 D76 ± 79 retains wildtype levels of inhibitory activity.
Next, we investigated the properties of the p21 mutants in the regulation of E2F activity on the cyclin A promoter. The introduction of p21
caused a reduction in transcriptional activity that was comparable to the eect of p21 1 ± 90 (Figure 5a , compare tracks 1, 2 and 5). As p21 D76 ± 79 retains wild-type levels of cdk2 kinase inhibitory activity (Figure 4b) , such a result could be consistent with p21
antagonising the cdkdependent regulation of pRb, and therefore acting through the previously recognized mechanism of phosphorylation control of the pRb/E2F interaction. Interestingly, however, although p21 21,24 and p21
could not inhibit cdk2 kinase activity (Figure 4b ), the p21 21,24 mutant derivative was capable of reducing the activity of the cyclin A promoter, in contrast to p21 D53 ± 58 ( Figure 5a , compare tracks 1, 2, 3 and 4). Since these data are derived from p21 derivatives that lack the PCNA interaction domain (Chen et al., 1994; Li et al., 1994; Gulbis et al., 1996) , the data imply that p21 can in¯uence E2F activity in a fashion that is independent of control exerted via the cdk/pRb pathway.
To characterize the p21 mutants further, we investigated their ability to regulate transcription as a Gal4 fusion protein. We found that although p21
could regulate cyclin A activity (Figure 5a , track 5), its capacity to down-regulate transcription as a Gal4 fusion protein was signi®cantly less ecient relative to the wild-type p21 hybrid (Figure 5b , compare tracks 2 to 5). As p21 D76 ± 79 can inhibit cdk2 kinase activity to a comparable extent as p21 1 ± 90 (Figure 4b ), these results argue that the regulation of transcription by a Gal4-p21 1 ± 90 hybrid protein may be exerted through a mechanism other than the control of cdk activity.
In contrast, when the activity of p21 21,24 and p21
was studied in the Gal4 hybrid assay, p21 21,24 but not p21 D53 ± 58 , was capable of causing a reduction in transcriptional activity (Figure 5b , compare tracks 2, 3 and 4). Since both of these mutant p21 derivatives are compromised in cdk2 kinase inhibition, the results on p21 21, 24 suggest that transcriptional control by p21 1 ± 90 in the context of a Gal4 hybrid protein can occur through a mechanism that is not absolutely dependent upon the inhibition of cdk2 kinase. This conclusion concurs with the analysis of p21
, which retains the ability to regulate cdk activity but cannot in¯uence transcription as a Gal4 hybrid.
Overall, therefore, a comparison of the properties of the p21 mutants (summarized in Figure 5c ) in the regulation of cdk2 kinase and E2F activity, together with their activity as Gal4 hybrid proteins, argues that p21 can in¯uence transcription through a pathway other than and in addition to the phosphorylation control of the pRb/E2F interaction.
p21 binds to E2F subunits
We reasoned that in the context of p21-mediated regulation of E2F that a component of the E2F heterodimer may physically associate with p21, thus providing the necessary means of targeting p21 to E2F-regulated promoters in an analogous fashion to the role of the Gal4 DNA binding domain in the Gal4-p21 hybrids and the pSV-GAL-tk promoter. To test this idea, p21 was expressed and puri®ed as a GST-fusion protein, incubated with a nuclear extract prepared from C33A cells, and thereafter associated proteins released and assayed by immunoblotting. Both E2F-1 and DP-1, which together form the E2F heterodimer Dyson, 1998) , bound to GST-p21 ( Figure 6 , tracks 5 and 10). This interaction was speci®c for wild-type p21 since a similar association between GST alone or the mutant derivative p21 134 ± 164 was not evident (Figure 6 , compare tracks 3, 4, 8 and 9). Furthermore, as the association between p21 and the cyclin/cdk complex located in the spacer region of the p107 pocket is believed to be competitive with cyclin/cdk binding to p107 (La Baer et al., 1997) , it is unlikely that the interaction of p21 with E2F subunits was indirectly mediated through a p21/cyclin/cdk complex within the p107 spacer region. In this respect, attempts to demonstrate the association of p107 with GST-p21 have been, as expected, unsuccessful (data not shown). Thus, the results on the association of p21 with E2F subunits are more consistent with a pocket proteinindependent association between p21 and E2F.
p21 can regulate transcription in vitro
Although the results so far suggest that p21 can regulate E2F-dependent transcription, they do not rule out the possibility that the observed eects measured through cyclin A promoter activity in transfected cells were caused through an indirect eect of p21 on cell cycle progression. Thus, if p21 were to possess biochemical properties that enabled it to modulate transcriptional activity in an in vitro assay, it would be more consistent with a direct eect of p21 on the transcriptional machinery and therefore cyclin A transcription.
To pursue this issue, we developed an in vitro transcription system and thereafter assessed the eects of Gal4-p21 on a Gal4-responsive promoter. This assay incorporated two dierent promoters that were each joined to a transcribed sequence derived from a G-less cassette (Kretzschmar et al., 1993; Ge and Roeder, 1994) . One reporter contained ®ve Gal4 binding sites positioned upstream of the TATA element of the human immunode®ciency virus type 1 (pMRG5) and
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Waf1/Cip1 L Delavaine and NB La Thangue the other, which served as the internal control, contained the adenovirus major late core promoter and lacked Gal4 binding sites (pMLD53), referred to Gal4 and IC respectively in Figure 7 . When the eect of puri®ed Gal4-p21 1 ± 90 protein was measured, a speci®c reduction in transcriptional activity derived from the Gal4-responsive template was apparent, in contrast to the much reduced eect on the internal promoter (Figure 7a, tracks 1, 2 and 3) . A mutant derivative of p21, Gal4-p21 28 ± 139 , which failed to eect E2F and lacked discernable activity in the Gal4-p21 hybrid assay (Figure 3) , was also studied. In contrast to the properties of Gal4-p21 1 ± 90 , we found that Gal4-p21 28 ± 139 had negligible eects in the in vitro transcription assay (Figure 7a , tracks 4 and 5). These results suggest that p21 can directly in¯uence transcription Figure 5 Properties of p21 mutant derivatives. (a) The cyclin A promoter fused to luciferase (2.0 mg) was introduced into U2OS cells together with expression vectors (2.0 mg) encoding Gal4-p21 1 ± 90 (track 2), Gal4-p21 21,24 (track 3), Gal4-p21 D53 ± 58 (track 4) or Gal4-p21 D76 ± 79 (track 5). pSV-bgal (2 mg) was introduced as the internal control and the values calculated as described earlier. (b) pSV-GAL-tk (200 ng) was introduced into U2OS cells together with the indicated expression vectors (2.0 mg) encoding and, in a fashion that is consistent with the data derived from the transfection experiments, support the idea that the eects are exerted when p21 is targeted to the promoter context.
To continue with the analysis of p21 on in vitro transcription, we assayed two additional p21 mutants as Gal4 fusion proteins, namely p21 21,24 and p21
. The earlier data showed that p21 21,24 can down-regulate cyclin A activity, reduce transcription as a Gal4 hybrid and that it has lower cdk2 kinase inhibitory activity; in contrast p21 D53 ± 58 did not aect activity in any of the assays (Table 1) . We found that the properties of these two mutant derivatives on in vitro transcription correlated with the eects observed in transfected cells, as 21,24 could reduce transcription of the Gal4-responsive promoter, but not the internal control promoter, whereas Gal4-p21 D53 ± 58 had little eect on the transcription from either template (Figure 7b , compare tracks 1 to 4). These results suggest that p21 can in¯uence transcription and that in order to do so the protein needs to be targeted to the promoter context. Furthermore, the analysis of the results derived from the p21 mutant derivatives imply that the mechanism is mediated through a process that is not likely to be critically dependent of the ability of p21 to function as a cdk2 antagonist in the pRb/E2F pathway or modulate PCNA activity.
Discussion
Regulation of E2F activity by p21
It is recognized that p21 can in¯uence cell cycle progression through plieotrophic mechanisms. In support of this idea, the p21 protein is composed of Figure 6 p21 associates with E2F subunits. Extract prepared from C33A cells (600 mg) was incubated with about 1 mg of GST (tracks 3 and 8), 134 ± 164 (tracks 4 and 9) or GST-p21 (tracks 5 and 10). Thereafter, GST fusion proteins were collected as described, and bound proteins released and detected by immunoblotting with antisera raised against either DP-1 (tracks 1 to 5) or E2F-1 (tracks 6 to 10). Tracks 2 and 7 show reactivity with the C33A extract and tracks 1 and 6 the molecular weight standards. Note that the slower migrating polypeptide in track 2, indicated by ., is a cross reacting polypeptide. The DP-1 and E2F-1 polypeptides are indicated by the bracket Figure 7 p21 regulates in vitro transcription. (a) In vitro transcription was performed in HeLa cell extracts and transcription derived from the Gal4-responsive promoter pMRG5 or the internal control pMLD53 (100 ng of each and indicated as Gal4 and IC respectively in the ®gure) containing the adenovirus major late promoter was assayed as described. The eect of adding Gal4-p21 1 ± 90 (tracks 2 and 3; 50 and 100 ng) or Gal4-p21 28 ± 139 (tracks 4 and 5; 50 and 100 ng) is shown. (b) In vitro transcription was performed as described in (a) and the eect Gal4-p21 21,24 (tracks 1 and 2; 50 and 100 ng) or Gal4-p21 D53 ± 58 (tracks 3 and 4; 50 and 100 ng) on transcriptional activity is shown at least two distinct functional domains, one of which is responsible for cyclin/cdk binding and inhibition and the other, which is located in the C-terminal half of the protein, for the direct association with PCNA (Chen et al., 1994) . Furthermore, p21 may have additional roles in augmenting the assembly of cyclin/cdk complexes (LaBaer et al., 1997) and controlling stress-activated protein kinases (Shim et al., 1996) . However, it is currently believed that one of the most signi®cant pathways through which p21 eects growth arrest is via the regulation of the pRb/E2F pathway (Sherr and Roberts, 1995) , as the inhibition of cdk activities that act upstream of pRb will maintain pRb in a hypophosphorylated state and thereby prevent the release of transcriptionally active E2F (Figure 8) .
Whilst supporting this general viewpoint, the data presented in this study imply that p21 may be endowed with properties in addition to those that already have been established to enable p21 to participate in regulating the activity of the pRb/E2F pathway. Speci®cally, our data indicate that p21 can regulate E2F in a pRb-independent fashion as well as downregulate transcription when targeted to a promoter context. Importantly, this ability to regulate transcription was apparent in vitro, thus minimizing the possibility that the eects of p21 observed in vivo were caused indirectly through p21 aecting cell cycle progression.
Furthermore, that such an activity of p21 is likely to be exerted in a manner that is not critically dependent upon cdk2 antagonism was supported by data obtained from an analysis of several p21 mutant derivatives. Of note were the properties of p21 21, 24 , which is mutated in the region that at a structural level is likely to ®t into the cyclin-box, and which we found in agreement with previous studied (Lin et al., 1996) possesses reduced ability to regulate cdk activity. However, p21
21,24 could down-regulate transcriptional activity both in vivo and in vitro, thus implying that p21 21, 24 , whilst reduced in ability to regulate cdk2 kinase activity, retains the capacity to in¯uence transcriptional activity (Figure 8) . In contrast to p21 21, 24 , p21 D76 ± 79 failed to aect transcription as a Gal4 hybrid protein although it possessed E2F and cdk2 kinase inhibitory activity. It is possible, therefore, that p21 D76 ± 79 in¯uences E2F activity through the classical route of modulating pRb through the inhibition of upstream cdk activity and the maintenance of pRb in a hypophosphorylated state (Figure 8) .
It is of signi®cant interest that the analysis of the p21 mutants identi®ed the integrity of the C-terminal half of p21 1 ± 90 as necessary for the regulation of transcription, since p21 D53 ± 58 and p21 D76 ± 79 were inactive as Gal4 hybrid proteins, in contrast to p21 21, 24 . Structurally, the region of p21 around residue 53 to 58 within the cyclin/cdk complex lies close to the catalytic cleft of the cdk subunit (Jerey et al., 1995) , suggesting perhaps that the mechanism through which p21 regulates transcription when localized to a promoter context involves modulating the activity of a catalytic subunit. However, as p21 21, 24 retains the ability to regulate transcription as a Gal4 hybrid, and it is this mutated region of p21 that in the wild-type protein is likely to ®t into the cyclin box (Jerey et al., 1995) , it is unlikely that a classical cyclin molecule is a critical target in the process. However, this analysis of p21 mutant derivatives does not rule out the possibility that a molecule with related structural motifs to the cyclin box is involved in mediating the observed eects.
The p21 protein is capable of regulating diverse types of protein-protein interactions. Indeed, in a general context p21 may modulate the interaction of kinases that signal upstream events to downstream multiprotein complexes, of which an example could be the transcription apparatus. In this respect, it is relevant that p21 can associate with E2F subunits which, in terms of the model presented in this manuscript, may provide the means of targeting p21 to a relevant promoter in an analogous fashion to the role of the Gal4 DNA binding domain in the context of Gal4-p21 hybrid proteins.
p21 may regulate E2F through diverse pathways of control
Studies on the role of p21 during the dierentiation of keratinocytes have suggested that p21 may play an important role in allowing cells to progress through and complete the dierentiation programme (Missero et al., 1996; Di Cunto et al., 1998) . A part of this process appears to involve the ability of p21 to modulate and down-regulate the activity of promoters, the transcription of which is induced during the terminal stages of dierentiation (Di Cunto et al., 1998) . For example, the involucin promoter is downregulated by p21 through a mechanism that may involve a modulation of the transcription machinery in non-cycling cells.
Our data provide further support for the idea that the activity of p21 can impact directly on transcription, and imply that p21 can employ diverse pathways towards the regulation of E2F activity. However, a question of considerable importance relates to the physiological relevance of the mechanisms described here. In this respect, we suggest that it is appropriate to consider that multiple modes of E2F regulation may be operational at dierent points in the cell cycle. For example, a cdk-dependent pathway that impinges on the activity of pRb may be of greater physiological Figure 8 Regulation of E2F activity by p21. Diagram indicating the pathways through which p21 can in¯uence cell cycle progression, namely via the regulation of cyclin/cdk activity and thereafter the maintenance of pRb in an active growth suppressing and hypophosphorylated state, or through the modulation of PCNA activity. The additional mechanism suggested by the present study, whereby p21 can in¯uence E2F activity through a pathway that is independent of controlling upstream cdks in the Rb/E2F pathway, is also presented signi®cance in regulating the transition through G1, namely in conditions where pRb is responsive to phosphorylation control. Consequently, a pathway that allows p21 to impact on E2F activity in a pRbindependent fashion may be of considerable significance in the later stages of the cell cycle, such as when cells have embarked on S phase and begun to progress towards G2, and thus passed through the cell cycle window in which pRb has an opportunity to regulate E2F (Figure 8 ). Of relevance to this idea is the large body of evidence linking p21 activity with cell cycle progression in G2 (Agarwal et al., 1995; Bunz et al., 1998; Dulic et al., 1998; Niculescu et al., 1998) .
In conclusion, our study suggests that p21 is capable of in¯uencing E2F activity through diverse mechanisms that act in addition to the control of upstream cdks that regulate the pRb/E2F interaction. The data suggest that an important aspect of this level of p21-dependent control is exerted by p21 protein that is placed in a promoter context, which thereafter allows p21 to in¯uence transcriptional activity. The results imply that this level of regulation involves an association between E2F subunits and p21. An important possibility that arises from this study is that the proposed mechanism may be relevant, at a more general level, to the physiological role of p21 in the regulation of transcription factor activity. In this respect, it will be interesting to further explore the mechanisms involved and assess if transcription factors other than E2F are subject to a similar level of control by p21.
Materials and methods
Expression vectors
The following expression vectors have been described previously; Gal4-pRb, Gal4-pRbD22 and Gal4-p107, pCMV-p21, pRcCMVHA-E2F-1 and E2F1-D5 and pCMV Y411C, (Bremner et al., 1995; El-Deiry et al., 1993; Helin et al., 1993; Krek et al., 1994) . Reporter constructs cyclin Aluciferase, thymidine kinase-luciferase, and pTG13 have been documented (Slansky et al., 1993; Zwicker et al., 1995; Lee et al., 1998) . To create pSV-GAL-tk, a BglII-XbaI fragment containing one Gal4 binding site and the minimal herpes virus thymidine kinase promoter from pGal4-tk-cat (Zamanian and La Thangue, 1993) was inserted into pGL3 digested with NheI and BglII. Sequences from the plasmids pBSKp21 21,24 and pBSK-p21 D53 ± 58 (Nakanishi et al., 1995; Lin et al., 1996) were ampli®ed and cloned into pcDNA3Gal4. The Gal4-p21 fusion plasmids were generated by PCR. The following primers were used to create Gal4-p21 1 ± 164 : 5'-CGG-GGATCCGTATGTCAGAACCGG CTG, 5'-TTGGGTAC-CTTAGGGCTTCCTCTTGGA. The PCR product was digested with BamHI and KpnI and introduced into pSG424. The plasmid was subsequently cut with Hind3 and XbaI and inserted into pcDNA3 (InVitrogen) to create pGal4-p21. Similarly, the following primers were used to create p21 1 ± 90 , p21 28 ± 90 , p21
28 ± 139 and p21 90 ± 139 respectively; 5'-CGGGGATCCGTATGTCAGAACCGGCT G and 5'-C-CGGTACCCCTCCTCCCAACTCATC for 1 ± 90, 5'-GGG-GATCCGTCAGCTGAGCCGCGACTG and 5'-CCGGTA-CCCCTCCTCCCAACTCATC for 28 ± 90, 5'-GGGGATCC-GTCAGCTGAGCCGCGACTG and 5'-GGGGATCCGTA-GGCGGCCTGGCACCTC and 5'-TAGGTACCCGACCC-TGAGAGTCT for 90 ± 139. pcDNA3 Gal4-p21 D76 ± 79 was prepared by amplifying p21 1 ± 90 as described together with to additional primers 5'-CTTGGGCAGGCCAAGGCC and 5'-ACGGGGCCCCGGCGAGGC and subsequently cloning by PCR-ligation-PCR mutagenesis (Ali and Steinkasserer, 1995) . All the PCR products were digested with BamHI and KpnI and manipulated as described above. Then GST-p21 was made by inserting a SmaI fragment from Gal4-p21 into pGEX.KG (Pharmacia). 135 ± 164 was made in a similar fashion. GST fusion proteins were expressed in BL21 DE3. Bacteria were induced with 1 mM IPTG for 2 h at 378C and lysed for 30 min in ice cold PBS containing 500 mM NaCl, 1% Triton X-100, 1 mM PMSF and 50 mg/ml soya bean trypsin inhibitor. After sonication, lysates were clari®ed at 20 000 r.p.m. for 30 min and the proteins puri®ed on glutathione agarose beads (Sigma).
Puri®cation of His-Gal4-p21 protein About 10 ml of an overnight culture was inoculated into 1 L of medium containing 30 mg/ml of kanamycin to an OD 600 of 0.7 and induced with 0.4 mM IPTG for 3 h at 378C. The bacterial pellet was resuspended in 30 ml of 20 mM Tris pH 7.9, 500 mM KCl, 0.1% NP40, 1 mM PMSF, 15 mM bmercaptoethanol and left on ice for 30 min. The lysate was sonicated (5620 s) and the insoluble fraction collected by centrifugation at 15 000 r.p.m. for 30 min. The bacterial pellet was resuspended in 10 ml of the above buer containing 2 mM MgCl 2 and 6 M urea and left overnight at room temperature. After soni®cation, cell debris was collected by centrifugation and the supernatant loaded on an 1 ml NTA column (Qiagen). The column was washed with ten column volumes of 20 mM Tris pH 7.9, 500 mM KCl, 1 mM PMSF and 40 mM imidazole and the protein eluted in the same buer containing 4 M urea and 250 mM imidazole. The fractions containing the protein were pooled, dialysed into 200 volumes of 20 mM Tris pH 7.9, 500 mM KCl, 0.5 mM EDTA, 1 mM DTT containing 4 M, 2 M, 1 M urea for 1 h each. The protein was then dialyzed overnight into buer D (25 mM HEPES pH 7.9, 100 mM KCl, 0.5 mM EDTA, 1 mM DTT containing 1 mM PMSF), which was then puri®ed on an Hi Trap Sp Sepharose (Pharmacia) column equilibrated in buer D. For in vitro transcription assays the fractions containing the protein were dialysed in buer D and stored at 708C.
Transfection
U2OS cells were transfected in duplicate when at about 60% con¯uence using the calcium phosphate procedure. After 24 h the cells were washed twice with PBS to remove traces of the precipitate and incubated for a further 24 h. Thereafter the cells were lysed and assayed for luciferase and b-galactosidase (Bandara et al., 1994) . Each transfection was repeated at least three times.
Kinase assay U2OS cells were transfected and lysed in 50 ml of lysis buer, 20 mM Tris pH 8, 420 mM NaCl, 0.5 mM EDTA, 0.1% NP40, 1 mM DTT, 20% glycerol, 50 mM b glycerophosphate, 10 mM NaF and protease inhibitors (Sigma) for 30 min on ice. After removing cell debris, the lysate was diluted 1 in 3 in 20 mM Tris pH 8 0.1% NP40 and immunoprecipitated with 1 ml of cdk2 antibody (SC-163-6) pre-bound to 10 ml of protein G (Calbiochem) for 2 h at 48C. Immunoprecipitates were washed three times in diluted lysis buer and twice in 20 mM Tris pH 8, 10 mM MgCl 2 . For the kinase assay, the beads were resuspended into 20 ml of 20 mM Tris pH 8, 5 mM DTT. 50 mM b glycerophosphate, 10 mM NaF, 10 mM MgCl 2 , 50 mM ATP, 1 mM PMSF, 5 mCi of ATP (10 m Ci/ml-Amersham) and 1 mg of histone H1 (Boehringer) for 30 min at 308C. The samples were resuspended in SDS loading buer and run on a 10% acrylamide gel.
Immunochemistry, binding assays and fractionation
Rabbit anti-DP1 polyclonal antibodies have been described previously (Bandara et al., 1993) . The rabbit anity puri®ed anti-p21 (AP8) antiserum was a kind gift from Dr J Gannon and T Hunt, and anti-p21 (C19), mouse E2F-1 (KH95) and Gal4 DBD antisera were obtained from Santa Cruz.
To assess protein levels, U2OS cells were transfected in 60 mm dishes with 5 mg of the corresponding Gal4-p21 expression vectors using calcium phosphate and 48 h after transfection whole cell extracts were prepared. Equal amounts of protein lysate from the transfected cells were analysed on SDS ± PAGE and transferred onto a nitrocellulose membrane. The membrane was blocked for 2 h in 5% BSA, 0.5% Tween 20 and probed with the mouse Gal4 DBD antibody (1/1000) in 5% BSA, 0.5% Tween 20 overnight at 48C. The membrane was then probed with an anti-mouse alkaline phosphatase conjugated secondary antibody (1/ 5000).
Nuclear extract from C33A or HeLa cells was prepared as described (Dignam et al., 1983) . For binding studies, 600 mg of extract was diluted in 1 volume of 500 mM NaCl, 20 mM HEPES pH 7.9, 0.1% NP40, 1 mM EDTA, 25 mM NaF, 1 mM Na orthovanadate, 1 mM PMSF, 5 mg/ml of each aprotinin, leupeptin and soyabean trypsin inhibitor. Extracts were precleared with 40 ml of glutathione beads for 2 h before incubation with 1 mg of the corresponding GST fusion proteins for a further 2 h. Beads were washed ®ve times in buer containing 500 mM KCl and resuspended in two bead volumes of SDS loading buer. Samples were then analysed by SDS ± PAGE followed by Western blotting using rabbit polyclonal anti-DP1 peptide antibodies (1/250) (Bandara et al., 1993) mouse monoclonal anti-E2F-1 KH95 (1/1000).
Proteins were detected using rabbit or mouse secondary alkaline phosphatase conjugated antibodies (Promega).
In vitro transcription assay
The template pMLD53 and pMRG5 have been described previously (Kretzschmar et al., 1993; Ge et al., 1994) . Reactions in 25 ml contained 80 mg of HeLa nuclear extract, 100 ng of each template, 0.1 mM of ATP and UTP, 0.1 mM of 3'-0-methyl GTP, 5 mM of CTP (Pharmacia) and 10 mCi of CTP (Amersham 3000 Ci/mmol) in 20 mM HEPES pH 7.9, 2 mM DTT, 100 ng/ml of BSA, 60 mM KCl, 10% glycerol, 7 mM MgCl 2 , 40 U of RNAse In (Promega). Extracts and template in reaction buer were incubated at 308C with the indicated amount of p21 protein for 30 min before addition of 10 mCi of CTP. The reaction was then allowed to proceed for 45 min at 308C and then stopped by adding 10 ml of 0.2 M EDTA containing 5 U of RNAse T1 (Boehringer) and placed at 378C for 10 min. The samples were then precipitated and analysed on a 5% acrylamide gel containing 8 M urea.
